Biogen Message Board - Msg: 336322

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen

BIIB 177.08

+0.4%

Dec 26 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: David D. Long who wrote (36)	10/8/1996 11:37:00 AM
From: Rick Lundberg	of 1686

David, "Rick - Who makes VLA4 small molecule antagonists? - Thanks!" Biogen does! We have produced several classes of sub-nanomolar inhibitors of VLA4 as the lead effort in our 3 year old chemistry effort. The first, an aerosol-delivered compound, will be tested in asthma - clinical trials to start in mid-'97. The second, an orally-available compound, will start clinical trials in late '97 nor '98 and will ultimately be targeted towards one or more of several inflammatory indfications (eg. ashthma, inflammatory bowel disease). There are other companies that are developing inhibitors of this pathway, but we believe that we are significantly ahead of them. Scientists at Biogen were the first to describe and define the pathway and we have a number of patents in the area. Let me know if you have additional questions. Rick Lundberg Biogen Investor Relations

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next